Search Results - "DOI, Toshihiko"

Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer by Sasaki, Akinori, Nakamura, Yoshiaki, Mishima, Saori, Kawazoe, Akihito, Kuboki, Yasutoshi, Bando, Hideaki, Kojima, Takashi, Doi, Toshihiko, Ohtsu, Atsushi, Yoshino, Takayuki, Kuwata, Takeshi, Akimoto, Tetsuo, Shitara, Kohei

“…Background Hyperprogressive disease (HPD) during treatment with anti-programmed death-1/programmed death-ligand 1 monoclonal antibodies has anecdotally been…”
Get full text

Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours by Naito, Yoichi, Nishida, Toshirou, Doi, Toshihiko

“…Gastrointestinal stromal tumours (GISTs) are soft-tissue sarcomas of the gastrointestinal tract. Surgery is the standard treatment for localised disease, but…”
Get full text

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer by Kojima, Takashi, Shah, Manish A, Muro, Kei, Francois, Eric, Adenis, Antoine, Hsu, Chih-Hung, Doi, Toshihiko, Moriwaki, Toshikazu, Kim, Sung-Bae, Lee, Se-Hoon, Bennouna, Jaafar, Kato, Ken, Shen, Lin, Enzinger, Peter, Qin, Shu-Kui, Ferreira, Paula, Chen, Jia, Girotto, Gustavo, de la Fouchardiere, Christelle, Senellart, Helene, Al-Rajabi, Raed, Lordick, Florian, Wang, Ruixue, Suryawanshi, Shailaja, Bhagia, Pooja, Kang, S Peter, Metges, Jean-Philippe

“…Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. In this open-label, phase III…”
Get full text

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies by Piha‐Paul, Sarina A., Oh, Do‐Youn, Ueno, Makoto, Malka, David, Chung, Hyun Cheol, Nagrial, Adnan, Kelley, Robin K., Ros, Willeke, Italiano, Antoine, Nakagawa, Kazuhiko, Rugo, Hope S., Braud, Filippo, Varga, Andrea Iolanda, Hansen, Aaron, Wang, Hui, Krishnan, Suba, Norwood, Kevin G., Doi, Toshihiko

“…We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE‐158 (NCT02628067; phase 2) and KEYNOTE‐028…”
Get full text

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies by Kumagai, Shogo, Togashi, Yosuke, Kamada, Takahiro, Sugiyama, Eri, Nishinakamura, Hitomi, Takeuchi, Yoshiko, Vitaly, Kochin, Itahashi, Kota, Maeda, Yuka, Matsui, Shigeyuki, Shibahara, Takuma, Yamashita, Yasuho, Irie, Takuma, Tsuge, Ayaka, Fukuoka, Shota, Kawazoe, Akihito, Udagawa, Hibiki, Kirita, Keisuke, Aokage, Keiju, Ishii, Genichiro, Kuwata, Takeshi, Nakama, Kenta, Kawazu, Masahito, Ueno, Toshihide, Yamazaki, Naoya, Goto, Koichi, Tsuboi, Masahiro, Mano, Hiroyuki, Doi, Toshihiko, Shitara, Kohei, Nishikawa, Hiroyoshi

“…Immune checkpoint blockade has provided a paradigm shift in cancer therapy, but the success of this approach is very variable; therefore, biomarkers predictive…”
Get full text

Immunotherapy for Esophageal Squamous Cell Carcinoma by Kojima, Takashi, Doi, Toshihiko

“…Esophageal squamous cell carcinoma have been frustrating to treat, with slow progress made on extending survival. Immunotherapy targeting immune checkpoints, T…”
Get full text

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer by Segal, Neil H, He, Aiwu R, Doi, Toshihiko, Levy, Ronald, Bhatia, Shailender, Pishvaian, Michael J, Cesari, Rossano, Chen, Ying, Davis, Craig B, Huang, Bo, Thall, Aron D, Gopal, Ajay K

“…Utomilumab (PF-05082566) is an agonistic mAb that engages the immune costimulatory molecule 4-1BB/CD137. In this first-in-human, phase I, open-label,…”
Get full text

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study by Strosberg, Jonathan, Mizuno, Nobumasa, Doi, Toshihiko, Grande, Enrique, Delord, Jean-Pierre, Shapira-Frommer, Ronnie, Bergsland, Emily, Shah, Manisha, Fakih, Marwan, Takahashi, Shunji, Piha-Paul, Sarina A, O'Neil, Bert, Thomas, Sajeve, Lolkema, Martijn P, Chen, Menghui, Ibrahim, Nageatte, Norwood, Kevin, Hadoux, Julien

“…KEYNOTE-158 (ClinicalTrials.gov identifier: NCT02628067) investigated the efficacy and safety of pembrolizumab across multiple cancers. We present results from…”
Get full text

Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients by Kurose, Koji, Ohue, Yoshihiro, Wada, Hisashi, Iida, Shinsuke, Ishida, Takashi, Kojima, Takashi, Doi, Toshihiko, Suzuki, Susumu, Isobe, Midori, Funakoshi, Takeru, Kakimi, Kazuhiro, Nishikawa, Hiroyoshi, Udono, Heiichiro, Oka, Mikio, Ueda, Ryuzo, Nakayama, Eiichi

“…FoxP3(+) Tregs inhibit immune responses against tumors. KW-0761 is a humanized anti-human CCR4 monoclonal antibody (mAb) that has antibody-dependent cellular…”
Get full text

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer by Mehnert, Janice M, Varga, Andrea, Brose, Marcia S, Aggarwal, Rahul R, Lin, Chia-Chi, Prawira, Amy, de Braud, Filippo, Tamura, Kenji, Doi, Toshihiko, Piha-Paul, Sarina A, Gilbert, Jill, Saraf, Sanatan, Thanigaimani, Pradeep, Cheng, Jonathan D, Keam, Bhumsuk

“…Treatment options for advanced thyroid cancer refractory to standard therapies are limited. The safety and efficacy of pembrolizumab were evaluated in patients…”
Get full text

Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein–Barr virus status in a large cohort of gastric cancer patients by Kawazoe, Akihito, Kuwata, Takeshi, Kuboki, Yasutoshi, Shitara, Kohei, Nagatsuma, Akiko Kawano, Aizawa, Masaaki, Yoshino, Takayuki, Doi, Toshihiko, Ohtsu, Atsushi, Ochiai, Atsushi

“…Background Antibodies against programmed death 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1) have recently demonstrated promising results in…”
Get full text

Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN— A Randomized, Phase III Study by SATOH, Taroh, XU, Rui-Hua, MIWA, Hiroto, QIN, Shu-Kui, CHUNG, Ik-Joo, YEH, Kun-Huei, FENG, Ji-Feng, MUKAIYAMA, Akihira, KOBAYASHI, Mikiro, OHTSU, Atsushi, BANG, Yung-Jue, HYUN CHEOL CHUNG, SUN, Guo-Ping, DOI, Toshihiko, XU, Jian-Ming, TSUJI, Akihito, OMURO, Yasushi, JIN LI, WANG, Jin-Wan

“…In Asian countries, paclitaxel once per week is used as second-line treatment in advanced gastric cancer, including human epidermal growth factor receptor 2…”
Get full text

Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8 + T cells in the tumor microenvironment by Tada, Yasuko, Togashi, Yosuke, Kotani, Daisuke, Kuwata, Takeshi, Sato, Eichi, Kawazoe, Akihito, Doi, Toshihiko, Wada, Hisashi, Nishikawa, Hiroyoshi, Shitara, Kohei

“…Several studies have established a correlation between the VEGF-VEGFR2 axis and an immunosuppressive microenvironment; this immunosuppression can be overcome…”
Get full text

Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan by Takushima, Yusuke, Igarashi, Ataru, Yoshihara, Hiroshi, Shitara, Kohei, Doi, Toshihiko

“…Abstract Objective Nivolumab and trifluridine/tipiracil have significantly improved the overall survival of patients with heavily pretreated metastatic gastric…”
Get full text

The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer by Kubota, Yohei, Kawazoe, Akihito, Sasaki, Akinori, Mishima, Saori, Sawada, Kentaro, Nakamura, Yoshiaki, Kotani, Daisuke, Kuboki, Yasutoshi, Taniguchi, Hiroya, Kojima, Takashi, Doi, Toshihiko, Yoshino, Takayuki, Ishii, Genichiro, Kuwata, Takeshi, Shitara, Kohei

“…We evaluated the association between molecular subtypes of advanced gastric cancer (AGC) and the efficacy of standard chemotherapy or immune checkpoint…”
Get full text

U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer by Koganemaru, Shigehiro, Kuboki, Yasutoshi, Koga, Yoshikatsu, Kojima, Takashi, Yamauchi, Mayumi, Maeda, Naoyuki, Kagari, Takashi, Hirotani, Kenji, Yasunaga, Masahiro, Matsumura, Yasuhiro, Doi, Toshihiko

“…HER3 is overexpressed in several cancers, including colorectal cancer. Although therapies with anti-HER3 antibodies have been investigated, significant…”
Get full text

Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab by Maeda, Yuka, Wada, Hisashi, Sugiyama, Daisuke, Saito, Takuro, Irie, Takuma, Itahashi, Kota, Minoura, Kodai, Suzuki, Susumu, Kojima, Takashi, Kakimi, Kazuhiro, Nakajima, Jun, Funakoshi, Takeru, Iida, Shinsuke, Oka, Mikio, Shimamura, Teppei, Doi, Toshihiko, Doki, Yuichiro, Nakayama, Eiichi, Ueda, Ryuzo, Nishikawa, Hiroyoshi

“…Regulatory T (Treg) cells are important negative regulators of immune homeostasis, but in cancers they tone down the anti-tumor immune response. They are…”
Get full text

Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study by Mehnert, Janice M., Bergsland, Emily, O’Neil, Bert H., Santoro, Armando, Schellens, Jan H. M., Cohen, Roger B., Doi, Toshihiko, Ott, Patrick A., Pishvaian, Michael J., Puzanov, Igor, Aung, Kyaw L., Hsu, Chiun, Le Tourneau, Christophe, Hollebecque, Antoine, Élez, Elena, Tamura, Kenji, Gould, Marlena, Yang, Ping, Stein, Karen, Piha‐Paul, Sarina A.

“…Background Despite a protracted disease course and multiple available therapies, patients with well‐differentiated neuroendocrine tumors (NETs) inevitably…”
Get full text

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study by Bang, Yung-Jue, Kang, Yoon-Koo, Catenacci, Daniel V., Muro, Kei, Fuchs, Charles S., Geva, Ravit, Hara, Hiroki, Golan, Talia, Garrido, Marcelo, Jalal, Shadia I., Borg, Christophe, Doi, Toshihiko, Yoon, Harry H., Savage, Mary J., Wang, Jiangdian, Dalal, Rita P., Shah, Sukrut, Wainberg, Zev A., Chung, Hyun Cheol

“…Background The multicohort, phase II, nonrandomized KEYNOTE-059 study evaluated pembrolizumab ± chemotherapy in advanced gastric/gastroesophageal junction…”
Get full text

Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer by Sasaki, Akinori, Nakamura, Yoshiaki, Togashi, Yosuke, Kuno, Hirofumi, Hojo, Hidehiro, Kageyama, Shunichiro, Nakamura, Naoki, Takashima, Kenji, Kadota, Tomohiro, Yoda, Yusuke, Mishima, Saori, Sawada, Kentaro, Kotani, Daisuke, Kawazoe, Akihito, Kuboki, Yasutoshi, Taniguchi, Hiroya, Kojima, Takashi, Doi, Toshihiko, Yoshino, Takayuki, Yano, Tomonori, Kobayashi, Tatsushi, Akimoto, Tetsuo, Nishikawa, Hiroyoshi, Shitara, Kohei

“…Background Immune checkpoint inhibitors may enhance the efficacy of radiotherapy (RT) in cancer treatment but the effect remains unknown in metastatic gastric…”
Get full text